Posterior reversible encephalopathy syndrome (PRES) and myeloma.
Cerebrovascular complication
Chemotherapy
Myeloma
Neurotoxicity
Posterior reversible encephalopathy syndrome
Journal
Leukemia research reports
ISSN: 2213-0489
Titre abrégé: Leuk Res Rep
Pays: England
ID NLM: 101608906
Informations de publication
Date de publication:
2024
2024
Historique:
received:
30
09
2023
revised:
23
12
2023
accepted:
28
12
2023
medline:
23
1
2024
pubmed:
23
1
2024
entrez:
23
1
2024
Statut:
epublish
Résumé
Posterior reversible encephalopathy syndrome (PRES) has rarely been described in myeloma, but chemotherapy is a known risk factor. We report 3 patients with myeloma who developed PRES, and analyzed them with 13 published cases, mostly women. The most frequent causative agents were proteasome inhibitors and autologous stem cell transplantation. Risk factors were frequently associated: hypertension, infection or renal failure. Symptoms included headache, blurred vision, altered mental status, seizures. Most patients experienced rapid clinical recovery, without relapse even after resuming treatment. Although rare, we must remain vigilant about PRES in myeloma patients. Stricter control of blood pressure could limit its occurrence.
Identifiants
pubmed: 38260821
doi: 10.1016/j.lrr.2023.100407
pii: S2213-0489(23)00047-X
pmc: PMC10801201
doi:
Types de publication
Case Reports
Langues
eng
Pagination
100407Informations de copyright
© 2024 The Authors. Published by Elsevier Ltd.
Déclaration de conflit d'intérêts
The authors have no conflict of interest related to this manuscript.